Print page
Email page
Download PDF
« Previous Release | Next Release »
Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data From the Second Fidaxomicin Phase 3 Trial
SAN DIEGO, April 22, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.
"Randomized Clinical Trial (RCT) in Clostridium difficile Infection (CDI)
Confirms Superiority of Fidaxomicin over Vancomycin"
Oral Presentation by: Stuart Johnson, M.D.
Tuesday, May 4, 2010 2:15pm-3:45pm Central Daylight Time
Abstract number: 828630
Location: Ballroom C, Ernest N. Morial Convention Center
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optmer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Porter Novelli Life Sciences
Jason I. Spark, Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved